Ellington Management Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Ellington Management Group’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-55,000	Closed	-$471K	–	693
2018 Q1	$471K	Buy	+55,000	New	+$509K	0.03%	425
2017 Q4	–	Sell	-24,100	Closed	-$296K	–	719
2017 Q3	$296K	Buy	+24,100	New	+$356K	0.05%	385
2016 Q3	–	Sell	-11,700	Closed	-$168K	–	666
2016 Q2	$168K	Sell	11,700 -15,600	-57%	-$212K	0.23%	175
2016 Q1	$326K	Buy	+27,300	New	+$286K	0.14%	215
2015 Q3	–	Sell	-15,000	Closed	-$121K	–	809
2015 Q2	$121K	Buy	+15,000	New	+$110K	0.03%	638

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CLM

ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

SGA

Sector Gamma AS Oslo, Norway $461M AUM 33.26% 1-Year Est. Return

Ellington Management Group's LXRX Position: Q2 2018 in Review

Ellington Management Group sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2018, closing a stake of 55,000 shares — an estimated $471K sold.

Ellington Management Group first reported a position in LXRX in Q2 2015 and held it in 5 quarters. The position peaked at $471K in Q1 2018. 121 funds tracked by Wall St. Rank hold LXRX as of Q2 2018.

Ellington Management Group reported no remaining Lexicon Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Ellington Management Group sold 55,000 Lexicon Pharmaceuticals shares in Q2 2018, an estimated $471K.
Ellington Management Group first reported a position in Lexicon Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Ellington Management Group's Lexicon Pharmaceuticals position peaked at $471K in Q1 2018.
121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.